Chemical reactions underlie core biologic processes. Chemists in our department study these reactions, synthesize bioactive molecules, and develop small molecule inhibitors. Early-stage drug discovery translates understanding of protein structure and function into entry-level screens for new cancer therapeutics.
Learn more about our Chemical Biology Program.
- The Gray Lab develops small-molecule chemical probes and inhibitor compounds to explore cellular processes that drive disease and to define therapeutic targets. Learn about the Center for Protein Degradation.
- The Buhrlage Lab is developing small molecules for therapies targeting deubiquitylating enzymes (DUBs) that inhibit the degradation of oncogenic proteins.
- The Qi Lab is designing small molecule inhibitors of epigenetic protein targets with therapeutic potential.
- The Kim Lab is exploring novel strategies to synthesize complex molecular architectures that provide opportunities for new therapeutic approaches.